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Abstract: Recent evidence showed that endogenous nicotinamide adenine dinucleotide phosphate-oxidase 4 
(NOX4) may exert a protective role on the cardiovascular system inducing vasodilation, reduction of blood pressure, 
and anti-proliferative actions. However, the functional significance of NOX4 in the cardiovascular system in humans 
remains elusive. Mononuclear cell levels of NOX4 were assessed by immunoblotting in 14 Gitelman’s patients 
(GS), a unique human model of endogenous Ang II signaling antagonism and activation of anti-atherosclerotic and 
anti-remodeling defenses,  and compared to 11 untreated essential hypertensive patients as well as to 11 healthy 
normotensive subjects. The association between NOX4 and its effector heme oxygenase (HO-1) (sandwich immu-
noassay) was also evaluated. NOX4 protein levels were decreased in hypertensive patients as compared to both 
GS and healthy subjects (1.06±0.31 AU vs. 1.76±0.54, P=0.002 and vs. 1.61±0.54, P=0.018, respectively). NOX4 
protein level did not differ between GS and healthy subjects. HO-1 levels were increased in GS patients as compared 
to both hypertensive patients and healthy subjects (8.65±3.08 ng/ml vs 3.70±1.19, P<0.0001, and vs 5.49±1.04, 
P=0.008, respectively. NOX4 levels correlate with HO-1 levels only in GS (r2=0.63; P=0.001), (r2=0.088; P=ns, in 
hypertensive patients and r2=0.082; P=ns, in healthy subjects). Our findings show that NOX4 and its effector HO-1 
are reduced in hypertensive patients compared to GS patients, a human model opposite to hypertension. Although 
the functional significance of NOX4 needs further clarification, our preliminary data in a unique human model of 
anti-atherosclerotic and anti-remodeling defenses activation, highlight the potentially protective role of NOX4 in the 
human cardiovascular system.
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Introduction
Patients with hypertension have increased oxi-
dative stress, which is involved in its patho-
physiology and is a central element in the 
hypertension induced cardiovascular and renal 
target organ damage [1]. Angiotensin II (Ang II) 
plays major roles in hypertension as it controls 
the processes of both blood pressure regula-
tion and cardiovascular remodeling. This is 
accomplished via different signaling systems. 
One, the short term signaling system, is acti-
vated by Ang II through the stimulation of the 
type 1 receptor (AT1R), which in turn activates 
calcium dependent pathways as well as RhoA/
Rho kinase pathways [2, 3]. The other, the long 
term signaling, which is linked to cardiovascu-
lar-renal remodeling occurs mostly through the 
induction of oxidative stress, via upregulation of 
the isoforms of the NADPH oxidase, namely 
NOX1 and NOX2, and MAP kinases activation 
including MAPK/ERK [2, 4]. NOX1 and NOX2 
represent the major source of superoxide anion 
(O2
-) in the vasculature. Increased superoxide in 
turn, may reduce the nitric oxide (NO) bioavail-
ability by NO scavenging [5].
NOX4 is another member of the NOX family of 
NADPH oxidases but Ang II, unlike its induction 
of NOX1 and NOX2, appears to inhibit NOX4 
expression in experimental models [6]. NOX4, 
unlike other NOXs, preferentially produces 
hydrogen peroxide (H2O2) while O2
- is produced 
at much lower extent [7]. This difference in 
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Table 1. Clinical and laboratory data of hypertensive patients, Gitelman’s patients, and normotensive healthy controls included in the study
Gitelman’s 
Patients Sex Age (yrs) Plasma Electrolytes (mmol/L) Urinary Electrolytes (mmol/day)
PRA (ng ANG 
I/ml/h)
Aldosterone 
(nmol/L)
Na+ K+ Cl- Mg++ Na+ K+ Cl- Ca++
1 F 27 138 2.3 96 0.69 199 38.6 195 2.4 12 0.94
2 F 30 137 2.9 99 0.63 255 38.0 200 1.9 9 0.70
3 M 44 140 2.8 98 0.60 198 30.8 220 2.0 7 0.88
4 F 31 138 2.7 98 0.60 297 42.8 289 2.1 10 0.78
5 M 32 138 3.0 99 0.56 200 81.5 239 2.0 6 0.67
6 F 58 140 3.0 100 0.55 190 42.5 220 2.0 6 0.70
7 M 29 139 3.0 100 0.57 190 42.5 218 2.1 6 0.75
8 M 31 139 3.1 100 0.58 192 42.8 210 2.2 6 0.75
9 M 43 139 3.0 98 0.58 200 45.4 197 2.0 5.8 0.80
10 M 39 139 2.8 97 0.59 195 47.4 198 2.0 5.8 0.81
11 F 30 139 2.9 100 0.60 196 48.8 199 2.0 6.1 0.77
12 F 29 138 3.0 101 0.61 200 47.6 200 2.3 6.6 0.78
13 F 34 140 2.8 98 0.65 195 43.0 195 2.0 5.9 0.75
14 F 28 139 2.7 100 0.62 199 42.0 196 2.1 6.4 0.75
Normotensive 
Controls (n=11)
6M/5F 46.2±10.5 140±1.0 4.1±0.2 99±0.97 0.99±0.2 180±16.5 52.8±4.8 179.8±19.6 4.5±0.5 0.73±0.13 0.18±0.02
Hypertensive 
patients (n=11)
6M/5F 49.6±11.2 142±0.9 4.1±0.1 99±0.94 1.1±0.2 188±19.5 56.9±6.0 178.2±16.6 4.4±0.6 0.99±0.15 0.24±0.06
The table reports single data of patients and controls. Normal values for PRA and plasma aldosterone in our laboratory are 0.2-2.8 ng ANG I/ml/h and 0.08-0.29 nmol/l respectively. 
Normal values for plasma Na+, K+, Cl-, Mg++ are 136-145, 3.5-5, 96-108, 0.65-1.05 mmol/l, respectively. Normal values for urinary Na+, K+, Cl- and Ca++  excretion are: 40-220, 25-
125, 110-250 and 2.5-7.5 mmol/day respectively.
NOX4 and angiotensin II signaling
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products may be significant as unlike O2
-, H2O2 
does not react with NO and may induce vasodi-
lation [7-9]. This difference might explain why 
recent experimental studies showed that 
endogenous NOX4 may exert a protective role 
on cardiovascular system by inducing vasodila-
tion and reduction of blood pressure [8] as well 
as by inducing anti-proliferative actions on cells 
from the vasculature [10]. However, despite 
these reported favorable effects, the functional 
significance of NOX4, particularly in the human 
cardiovascular system, remains undetermined 
[6].
Gitelman’s syndrome (GS) is a rare disease 
caused by mutations in the gene coding for the 
thiazide sensitive Na-K cotransporter (NCC/
SLC12A3), which induce hypokalemia, salt 
wasting, hypomagnesemia, hypocalciuria and 
increased Ang II and aldosterone levels yet nor-
mal or even low blood pressure [11]. These 
patients show blunted short and long term Ang 
II signaling via AT1R [12-14], reduced oxidative 
stress [14, 15], lack of cardiovascular remodel-
ing [14, 16, 17], upregulation of NO system [12, 
14], increased NO mediated vasodilation [14, 
16] and activation of Ang II signaling via AT2R 
[14, 18]. In addition BG/GS patients have also 
increased expression of heme oxygenase (HO) 
-1 [14, 15], which protects from oxidative stress 
and tissue inflammation [19, 20]. These 
patients thus likely represent a human model 
of endogenous Ang II signaling antagonism and 
activation of anti-atherosclerotic and anti-
remodeling defenses [14]. Interestingly, in- 
creased expression of HO-1 has been related to 
NOX4 activation [6]. All the above mentioned 
characteristics make these patients a unique 
human model in which to study the links 
between Ang II signaling, NOX4 and NO bio-
availability in a clinical setting.
This preliminary study was specifically done to 
provide an exploratory assessment of the lev-
Table 2. SLC12A3 mutations identified in the patients with Gitelman’s syndrome 
Patient Exon Mutation at nucleotide Homo-hete-rozygous Predicted effect on protein
1 23 2736G---->A homozygous Arg904Gln
2 22 2579C---->T heterozygous Arg852Cys
23 2736G---->A heterozygous Arg904Gln
3 15 1950G---->A heterozygous Arg642His or splice donor site truncated SLC12A3 protein
18 2246G---->A heterozygous Gly741Arg
4 22 2579C---->T heterozygous Arg852Cys
23 2736G---->A homozygous Arg904Gln
5 22 2579C---->T heterozygous Arg852Cys
23 2736G---->A heterozygous Arg904Gln
6 21 2542G---->T heterozygous Asp848Tyr
10 c.1196_1202dup 7bp heterozygous Ser402X
7 21 2542G---->T heterozygous Asp848Tyr
10 c.1196_1202dup 7bp heterozygous Ser402X
8 17 c.2089_2095del 7bp heterozygous pThr697fs
26 2985G--->A heterozygous Ser402X
9 17 c.2089_2095del 7bp heterozygous pThr697fs
26 2985G--->A heterozygous Ser402X
10 10 1195C--->T heterozygous pArg399Cys
15 1220C--->T heterozygous pArg642His
11 26 2981G--->A heterozygous pCys994Tyr
26 3005G--->A heterozygous pTrp1002*
12 15 1948G--->A heterozygous pGly650Arg
9 1180+1G--->T heterozygous Splicing site
13 15 1948G--->A heterozygous pGly650Arg
14 25 2954G--->A homozygous Cys985Tyr
NOX4 and angiotensin II signaling
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els of NOX4 and HO-1 in mononuclear cells 
from our cohort of GS patients compared with 
those in hypertensive patients and healthy nor-
motensive subjects using the unique human 
model of GS, opposite to hypertension, to 
obtain information on NOX4 level, its relation-
ship with Ang II signaling, its possible implica-
tions in hypertension and biological role in the 
cardiovascular system.
Material and methods
Patients
Fourteen patients (6 males and 8 women, age 
35.8±9.3 years) from our cohort of GS patients 
were included in the present study. All patients 
had a full biochemical characterization (Table 
1) and full genetic analysis (Table 2).
Eleven uncomplicated, nonsmoking and never 
treated essential hypertensive patients (6 
males, 5 females, age 49.6±11.2 years) were 
selected from the patient population seen at 
the Padova Hypertension Clinic, Department of 
Medicine, and enrolled in the study.
A total of 11 normotensive healthy individuals, 
(6 males, 5 females, age 46.2±10.5 years) 
from the staff of the Department of Medicine, 
University of Padova, were studied as control 
group.
Figure 1. Mononuclear cell NOX4 protein level in essential hypertensive patients (EH), Gitelman’s patients (GS) and 
normotensive healthy subjects (C). **P=0.002; *P=0.018.
NOX4 and angiotensin II signaling
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All the subjects included in the study had the 
following parameters in the normal range: BMI 
(< 25 kg/m2), fasting serum glucose (< 126 
mg/dl), serum creatinine (< 1.0 mg/dl) and uri-
nary albumin excretion (< 30 mg/g of urinary 
creatinine). Lipid profiles were normal, and the 
patients were not taking lipid-lowering drugs or 
aspirin. All the subjects were on regular 
Mediterranean diet, the salt consumption was 
approximately 150 mmol of sodium/day. The 
GS patients were taking potassium and magne-
sium supplements.
None of the patients had cardiac failure or evi-
dence of coronary heart disease; left ventricu-
lar hypertrophy was ruled out by conventional 
M-mode echocardiography.
Informed consent was obtained from all the 
study participants and the study protocol was 
approved by our institutional authorities.
All of the subjects abstained from food, alcohol 
and caffeine-containing drinks for at least 12 h 
before blood withdrawal.
Mononuclear cell NOX4 protein expression
Peripheral blood mononuclear cells were iso-
lated by Ficoll Paque Plus gradient (GE 
Healthcare, Uppsala, Sweden) from 35 ml of 
EDTA anticoagulated blood. Mononuclear cell 
NOX4 protein expression was performed using 
western blot analysis.  Total protein extracts 
were obtained by cells lysis with a ice-cold buf-
fer (Tris HCl 20 mM, NaCl 150 mM, EDTA 5.0 
mM, Niaproof 1.5%, Na3VO4 1.0 mM, SDS 0.1%, 
PMSF 0.5 mM) added with protease inhibitors 
(Complete Protease Inhibitor Cocktail, Roche 
Diagnostics, Mannheim, Germany). Proteins 
were separated by SDS-PAGE, transferred onto 
nitrocellulose membranes (Hybond ECL, 
Amersham, Uppsala, Sweden) and blocked 
overnight with no-fat milk (5% in Tween-PBS). 
Membranes were probed with primary poly-
clonal antibody anti-Nox4 (SantaCruz Bio- 
technology, SantaCruz, CA, USA). After incuba-
tion with proper secondary antibodies HRP-
conjugated (Amersham Biosciences, Uppsala, 
Sweden), immunoreactive proteins have been 
visualized with chemiluminescence using Su- 
perSignal WestPico Chemiluminescent Sub- 
strate (Pierce, Rockford, USA). GAPDH was 
used as loading control (Millipore, Billerica, MA, 
USA). Nox-4 protein expression was quantified 
using a densitometric semiquantitative analy-
sis using NIH image software, and was normal-
ized to GAPDH used as loading control.
Heme oxygenase-1 protein quantification
Total protein extracts from peripheral blood 
mononuclear cells were obtained by cell lysis 
Figure 2. Mononuclear cell Heme Oxygenase (HO)-1 protein level in essential hypertensive patients (EH), Gitelman’s 
patients (GS) and normotensive healthy subjects (C). ***P=0.0001; **P=0.008; *P=0.009.
NOX4 and angiotensin II signaling
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with an ice-cold buffer (Tris HCl 20 mM, NaCl 
150 mM, EDTA 5.0 mM, Niaproof 1.5%, Na3VO4 
1.0 mM, SDS 0.1%), with protease inhibitors 
added (Complete Protease Inhibitor Cocktail, 
Roche Diagnostics, Mannheim, Germany). Pro- 
tein concentration was evaluated by bicincho-
ninic acid assay (BCA Protein Assay, Pierce, 
Rockford, IL, USA).
An equal amount of total protein was used for 
the determination of HO-1, using a sandwich 
immunoassay for the detection and quantita-
tion of human HO-1 protein in cell lysates, 
according to the manufacturer’s specifications 
(Stressgen Bioreagents, Ann Arbor, MI, USA). 
After the test, absorbance was measured at 
450 nm. The resulting readings were plotted 
against a standard curve to determine the con-
centration of HO-1 in each sample (ng/ml). The 
intra-assay and inter-assay coefficients of vari-
ation were both <10%.
Statistical analysis
Heme oxygenase-1 protein Gaussian distribu-
tion was achieved by log transformation and 
confirmed at Kolmogorov-Smirnov test. Com- 
parison of quantitative variables across groups 
was carried out by ANOVA followed by 
Bonferroni’s post hoc test. The association 
yet normo-hypotension [11]. In addition the 
diagnosis had been confirmed by the identifica-
tion of the mutations on the SLC12A3 gene 
coding for the thiazide sensitive Na-K cotrans-
porter responsible of the syndrome [11] (Table 
2).
GS patients’ systolic blood pressure ranged 
from 105 to 120 mmHg and the diastolic blood 
pressure ranged from 60 to 72 mmHg.
In hypertensive patients the systolic blood 
pressure ranged from 142 to 156 mmHg, the 
diastolic blood pressure ranged from 94 to 98 
mmHg. In these patients the diagnosis of 
essential hypertension was confirmed by the 
exclusion of secondary hypertension via the 
evaluation of plasma renin activity and plasma 
aldosterone before and after 50 mg of captopril 
(captopril test).
Systolic blood pressure in normotensive healthy 
subjects ranged from 124 to 134 mmHg and 
the diastolic blood pressure from 79 to 83 
mmHg.
The levels of NOX4 in the different groups of 
subjects studied are presented in Figure 1.
NOX4 protein levels were decreased in hyper-
tensive patients as compared to both GS and 
Figure 3. Correlation analysis between NOX4 protein level and Heme Oxygen-
ase (HO)-1 in GS patients.
between NOX4 and HO-1 
was completed at linear 
regression analysis.
Data were expressed as 
means±SDs and were ana-
lyzed using the JMP (ver. 9.0) 
(SAS, Cary, NC, USA) statisti-
cal package running on a 
Mac Pro (Apple, Cupertino, 
CA). Values at less than 5% 
level (P<0.05) were consid-
ered significant.
Results
All the GS patients of our 
cohort, as shown in Table 1, 
exhibited the biochemical 
characteristics of the syn-
drome: low plasma K, salt 
wasting, hypomagnesemia, 
hypocalciuria and activation 
of the renin-angiotensin-
aldosterone system (RAAS) 
NOX4 and angiotensin II signaling
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healthy subjects (1.06±0.31 densitometric 
units (d.u.) vs 1.76±0.54, P=0.002 and vs 
1.61±0.54 P=0.018, respectively).
NOX4 protein level did not differ between GS 
and healthy subjects (1.76±0.54 d.u.) vs 
1.61±0.54, P=ns).
HO-1 levels were increased in GS patients as 
compared to both hypertensive patients and 
healthy subjects (8.65±3.08 ng/ml vs 
3.70±1.19, p=0.0001, and vs 5.49±1.04, 
P=0.008, respectively, Figure 2).
The protein levels of HO-1 in mononuclear cell 
were significantly reduced in hypertensive 
patients compared to healthy normotensive 
control subjects (3.70±1.19 ng/ml vs 
5.49±1.04 ng/ml, P=0.009, Figure 2).
As presented in Figure 3 NOX4 levels were posi-
tively correlated with HO-1 levels (r2=0.63; 
P=0.001) in GS patients.
In healthy subjects or in the essential hyperten-
sive patients no correlation was observed 
between NOX4 and HO-1 (r2=0.082; p:ns, 
r2=0.088; p:ns, respectively).
Discussion
Major findings of the present study are that: 1) 
GS patients characterized by endogenous 
antagonism of Ang II signaling [14] presented 
with NOX4 levels indistinguishable from normal 
subjects, whereas hypertensive patients had 
reduced NOX4 levels; 2) the protective HO-1 
protein was increased only in GS patients and 
positively correlated with NOX4 levels.
Ang II production is enhanced in hypertension 
and, through activation of its signaling via AT1R 
stimulation, plays a central role in the develop-
ment of target organ damage by inducing oxida-
tive stress upregulating the isoforms NOX1 and 
NOX2 of the NADPH oxidase, the major O2
- gen-
erating enzyme in the cardiovascular system 
[21]. ROS increase leads to the uncoupling of 
endothelial NO synthase, and to the reduction 
of NO synthesis as well as to the loss of NO 
associated antioxidant and vasodilating 
actions. These effects are in part due to the 
reduction of NO bioavailability and the 
increased production of the highly reactive oxi-
dant specie ONOO- as a result of the reaction 
between O2
- and NO [22].
NOX4 is the NOX homolog that induces prefer-
entially the production of H2O2 [7]. The function-
al significance of NOX4 is still not fully elucidat-
ed [6]. In order to study the linkage between 
Ang II and NOX4 in humans we studied the GS 
patients, which present increased Ang II levels, 
blunted Ang II signaling effects, normotension 
or hypotension. Previously we have extensively 
studied these patients in order to better under-
stand the mechanistic details of the cellular, 
biochemical and molecular events involved in 
Ang II signaling in humans [12-14] independent-
ly of high blood pressure, since GS do not 
develop hypertension and cardiovascular 
remodeling in spite of high Ang II levels and 
activation of the renin-angiotensin-aldosterone 
system (RAAS) [14]. The findings of the present 
study contribute to further extend the knowl-
edge on the linkage of Ang II with the NOX fam-
ily member NOX4.
NOX4 levels were higher in GS patients than 
hypertensive patients, and similar to the levels 
found in normotensive subjects. All this sug-
gests that, in humans, Ang II may contribute to 
the reduction of NOX4 levels, particularly in 
hypertension. The increased level of HO-1 in GS 
patients in contrast to the reduced levels found 
in hypertensive patients might be related to the 
increased NOX4 expression in these patients 
as maintenance/increase of HO-1 expression 
has been shown to be a downstream effect of 
NOX4 activity [9]. In this regard, the existence 
of a relationship between HO-1 and NOX4 is 
further bolstered by the statistically significant 
linear correlation between HO-1 and NOX4 
found in GS patients. Interestingly, we previ-
ously found an upregulation of nitric oxide sys-
tem and increased flow mediated dilation 
(FMD), a measure of endothelium dependent 
and nitric oxide-mediated response in the vas-
culature in our GS patients [14, 16]. Moreover 
GS patients also exhibited a significant correla-
tion between HO-1 protein levels and FMD [23]. 
Taken altogether, these findings in GS support 
a protective role of NOX4 activity in the human 
cardiovascular system. Opposite this is a case 
for reduced NOX4 levels being harmful as lower 
levels were found in our hypertensive patients. 
Hypertensive patients are characterized by 
RAAS activation, downregulation of NO system, 
reduced FMD [24], and activation of proinflam-
matory pathways of vascular remodeling [2]. 
These lower levels also suggest that NOX4 
NOX4 and angiotensin II signaling
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might be inhibited by Ang II particularly in hyper-
tension. However, the nature of the relationship 
between NOX4 levels and its cardiovascular 
effects is complicated by studies reporting neg-
ative effects for elevated levels. These studies 
found that excessive production of H2O2 in- 
duced by increased levels of NOX4 was proin-
flammatory and proliferative [25] and contrib-
uted to the increased oxidative stress related 
to stroke as well as the induction of neurode-
generation [26]. These negative effects have in 
part been related to elevated NOX4 in the pres-
ence of growth factors such as TGFβ [5]. Of 
note, while GS patients presented with similar 
NOX4 levels as normotensive subjects, they 
have reduced TGFβ gene expression both at 
baseline and after Ang II challenge [14,15]. 
Thus it is conceivable that NOX4 might be 
involved in vascular damage at very low or very 
high expression levels. It has been recently 
underlined the possible “multifarious” nature 
of NOX4 at vascular level and suggested that 
the divergent effects, vasodilation and cardio-
vascular protective effects or vasoconstriction, 
reduced NO bioavailability, endothelial dysfunc-
tion and remodeling, might relate to the relative 
levels of NOX4 generated H2O2 production com-
pared with the NOX4 mediated O2
- production 
[6].
In conclusion, our preliminary findings show 
that NOX4 protein expression and HO-1 level 
are reduced in hypertensive patients compared 
to GS patients. One limitation of this study is 
the small number of hypertensive and control 
patients enrolled but those numbers were 
inherent in the preliminary nature of this study. 
Another potential limitation is the use of circu-
lating cells rather than vascular cells, the major 
target of this system.  However, circulating 
blood cells are widely used in vascular biology 
to study “ex vivo” the pathophysiological mech-
anisms of hypertension and remodeling in 
humans [12-14, 27]. In addition, the role of 
inflammation and the mononuclear leucocyte 
infiltration in the development of hypertensive 
target organ damage has been increasingly rec-
ognized in the last few years [27]. Furthermore, 
a correlation between hypertension and intra-
cellular oxidative stress in leucocyte (polymor-
phonuclear and mononuclear cells) has recent-
ly been demonstrated [28].
The factors determining NOX4 activation and 
its ultimate effects still need a characteriza-
tion, but the involvement of Ang II signaling via 
AT2R, and/or the ACE2-Ang 1-7-Mas axis and/or 
the Ang 1-9 system might appear likely. Indeed, 
these systems may counteract the vasocon-
striction, the inflammatory process, and cardio-
vascular remodeling through multiple mecha-
nisms including NO production, the negative 
regulation of the RhoA/Rho kinase pathway 
and reduction of oxidative stress [14, 29-32]. 
This would then make studies in GS patients 
even more informative given the activation of 
AT2R signaling and the changes in ACE2-Ang 
1-7 system found in these patients [14]. Thus, 
our preliminary findings support further studies 
including a larger number of hypertensive 
patients in order to more clearly connect NOX4 
and HO-1 axis with Ang II signaling and its long 
term effects and how they are related to help in 
assessing the functional significance of NOX4 
in cardiovascular system in humans.
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